Close to half of adults and one quarter of kids in the US regularly consume artificial sweeteners

Low-calorie sweeteners (LCSs) are often used in place of added sugars such as sucrose and high-fructose corn syrup in food and beverage products. While these artificial sweeteners offer less calories, their effects on weight management and long-term health are still under investigation. A new study in the Journal of the Academy of Nutrition and Dietetics reports that 41% of adults and 25% of children currently consume at least one LCS item on a regular basis. The researchers note that this represents a 200% increase for children and a 54% increase among adults compared to data reported in 1999-2000.

Are LCSs good for you? "Although LCSs were once believed to be physiologically inert, more recently their use has been suggested to influence metabolism," noted lead investigator Allison C. Sylvetsky, PhD, assistant professor of Exercise and Nutrition Sciences at the George Washington University Milken Institute School of Public Health. "Some studies have suggested a beneficial effect on weight loss, while others indicate that obesity risk increases with LCS use. Little is known about the impact of long-term consumption, particularly in children. Despite the perceived benefits of replacing caloric sugars with LCSs for weight loss, evidence for the effectiveness of this strategy is lacking and some studies suggest a link between LCSs and obesity, diabetes, and other health issues."

Using data from the 2009-2012 National Health Examination Survey (NHANES), investigators analyzed reported LCS consumption for both children and adults. Data showed that women were more likely to consume products containing LCSs and that consumption increased with body weight in adults, with people with obesity being more likely to consume LCSs than normal weight individuals. Adults with diabetes were more likely to consume LCSs compared to those without diabetes. The data also showed a relationship between LCS intake and race and income. People of non-Hispanic white race/ethnicity had higher rates of LCS consumption, as did those in higher income brackets.

Researchers noted that while parents are generally opposed to feeding their kids food or drinks containing LCSs based on prior research, they may not realize that many of the foods children bring home surprisingly contain artificial sweeteners. In addition, LCSs are now being incorporated into foods not traditionally thought of as high in sugar like yogurt, milk substitutes, breads, cereals, condiments, and drinks.

"We have previously reported that most parents have negative attitudes toward LCS consumption by their children, yet often do not recognize the presence of LCSs in foods and beverages that they purchase for their families," explained Dr. Sylvetsky. "This study raised the possibility that parents may preferentially select products with nutrient content claims such as 'no sugar added' or 'light' in an effort to provide healthier options to their children, without realizing that these sugar-modified products often contain LCSs. The presence of LCSs in foods commonly consumed by children, such as canned fruit, ice cream, flavored oatmeal, and snack bars, combined with strong marketing and promotion of products deemed to be healthier alternatives, may be driving LCS food intake in children."

The study also found that most reported LCS consumption occurs at home (71% and 72% among adults and children, respectively) and with meals (64% of adults, 62% of children). While LCSs still represented a relatively low overall proportion of total food intake, 44% of adults and 20% of children reported consuming multiple daily servings of LCSs. For 17% of LCS-consuming adults, that number was more than three times per day.

"While the effects of early life exposure to LCSs on taste preferences, weight management, and chronic disease prevention have not been well-studied in humans, compelling findings in animal models highlight the need to examine their potential health effects in humans," concluded Dr. Sylvetsky. "Given that a significant proportion of children and adults in the US consume LCSs, these findings emphasize the need for prospective, long-term, well-controlled studies to determine the chronic health effects, especially in children."

Allison C. Sylvetsky, Yichen Jin, Elena J. Clark, Jean A. Welsh, Kristina I. Rother, Sameera A. Talegawkar.
Consumption of Low-Calorie Sweeteners among Children and Adults in the United States.
Journal of the Academy of Nutrition and Dietetics, January 2017, doi: 10.1016/j.jand.2016.11.004.

Most Popular Now

Top 20 World Pharma News of 2016

Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news accord...

Read more

New precision medicine tool helps optimize cancer …

Columbia University Medical Center (CUMC) researchers have created a computational tool that can rapidly predict which genes are implicated in an individual's cancer and ...

Read more

Roche's emicizumab for haemophilia A meets primary…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 y...

Read more

Sanofi and Boehringer Ingelheim confirm Closing of…

Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) an...

Read more

Diabetes, heart disease, and back pain dominate US…

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending ...

Read more

FDA approves first drug for spinal muscular atroph…

The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare ...

Read more

Novartis invests in next generation therapies to r…

Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...

Read more

Topical treatment activates immune system to clear…

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patie...

Read more

Vaccine shows promising results for early-stage br…

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer ...

Read more

Bristol-Myers Squibb announces immunotherapy clini…

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squi...

Read more

Anti-aging therapies targeting senescent cells: Fa…

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate w...

Read more

Novo Nordisk and Glooko partner to develop digital…

Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabet...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]